Saturday 17 October 2026
Export DGX’s income statement to Excel — free account
Quest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 14.7%, free cash flow grew 5.28% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
235.00
4.15
−1.74%
Follow DGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
22.06 | 19.56 | 21.37 | 22.22 |
P/S ratio |
1.97 | 1.75 | 1.91 | 2.04 | |
P/FCF ratio |
15.32 | 14.17 | 16.26 | 17.44 | |
P/Operating CF |
37.91 | 41.42 | 77.55 | 39.41 | |
P/B ratio |
2.93 | 2.67 | 2.81 | 3.01 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.45 | 2.22 | 2.38 | 2.47 | |
EV/EBITDA |
12.72 | 11.53 | 12.27 | 12.92 | |
EV/Operating CF |
14.11 | 13.00 | 14.50 | 15.00 | |
EV/FCF |
19.09 | 18.04 | 20.23 | 21.16 | |
Quick Ratio |
0.88 | 0.80 | 0.91 | 1.28 | |
Current Ratio |
1.13 | 1.04 | 1.18 | 1.59 | |
Net Debt/EBITDA |
9.93 | 9.89 | 9.64 | 8.29 | |
Debt/Assets |
35.04% | 34.95% | 33.94% | 33.31% | |
Debt/Equity |
0.78 | 0.79 | 0.74 | 0.72 | |
Asset Turnover |
0.67 | 0.68 | 0.69 | 0.70 | |
Operating CF/Net income |
2.30 | 1.93 | 1.10 | 1.87 | |
Capex/Depreciation |
(1.01) | (1.09) | (0.78) | (0.95) | |
Interest Coverage |
5.85 | 6.03 | 6.33 | 7.29 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
17.79% | 17.96% | 17.41% | 17.38% | |
Intangible Assets out of Total Assets |
0.65 | 0.65 | 0.65 | 0.64 | |
Share Based Compensation of Revenue |
0.71% | 0.89% | 0.69% | 0.76% | |
Graham Net Nets |
(0.30) | (0.34) | (0.30) | (0.27) | |
Graham Number |
112.53 | 113.83 | 119.91 | 122.96 | |
Earnings Yield |
4.53% | 5.11% | 4.68% | 4.50% | |
Free Cash Flow Yield |
6.53% | 7.06% | 6.15% | 5.73% | |
Revenue per Share |
25.14 | 25.28 | 26.32 | 27.41 | |
Operating CF per Share |
5.03 | 4.19 | 2.53 | 5.38 | |
Capex per Share |
(1.29) | (1.42) | (1.04) | (1.24) | |
Free Cash Flow per Share |
3.74 | 2.77 | 1.49 | 4.14 | |
Cash per Share |
3.86 | 3.78 | 3.57 | 5.64 | |
Shareholders Equity per Share |
65.13 | 64.92 | 69.69 | 70.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
65.13 | 64.92 | 69.69 | 70.44 | |
Free Cash Flow |
419.00 | 307.00 | 164.00 | 459.00 | |
Working Capital |
273.00 | 100.00 | 389.00 | 1,056.00 | |
Capital Expenditures |
(144.00) | (158.00) | (114.00) | (138.00) | |
Net Current Asset Value |
(6,495.00) | (6,641.00) | (6,441.00) | (6,276.00) | |
EV/EBIT |
17.37 | 15.75 | 16.67 | 17.51 | |
Capex to Sales |
0.05 | 0.06 | 0.04 | 0.05 | |
Price to Operating Income |
13.94 | 12.38 | 13.40 | 14.43 | |
| Other line items | |||||
Average Receivables |
1,416.00 | 1,356.00 | 1,495.50 | 1,542.50 | |
Average Payables |
1,385.00 | 1,497.00 | 1,383.50 | 1,473.50 | |
Average Inventory |
185.00 | 188.50 | 207.00 | 210.00 | |
Average Assets |
16,146.00 | 16,189.00 | 16,235.00 | 16,454.00 | |
Average Common Equity |
7,068.00 | 7,009.50 | 7,314.00 | 7,542.00 |
Columns are period end dates